Seattle Genetics Introduces Phase 1 Trial of SGN-CD33A in Acute Myeloid …
Seattle Genetics Introduces Phase 1 Trial of SGN-CD33A in Acute Myeloid …
Filed under: Seattle Drug Treatment Centers
In a release, the company noted that SGN-CD33A is a novel antibody-drug conjugate (ADC) utilizing Seattle Genetics' newest ADC technology targeted to CD33, which is expressed on most AML cells. The CD33 antibody is … "AML is a devastating disease …
Read more on HispanicBusiness.com
Myelin Peptide Skin Patch Safe, Reduces MS Activity
Filed under: Seattle Drug Treatment Centers
Unlike current MS drugs that inhibit a major immune function and often eliminate a wide array of immune cells, the myelin peptide patch targets MS-related antigens while sparing mechanisms critical for immune protection, Dr. Selmaj told Medscape …
Read more on Medscape
Statins improve symptoms in Rett mouse model
Filed under: Seattle Drug Treatment Centers
Treatment with a cholesterol-lowering statin drug lengthened the lifespan and improved some symptoms of the disorder in the mice, said a group of researchers led by those at Baylor College of Medicine in a report that appears online in the journal …
Read more on BCM News
Answers About Rheumatoid Arthritis, Part 2
Filed under: Seattle Drug Treatment Centers
Dr. Bykerk, a rheumatologist who has practiced for more than 20 years, is the director of research at the Inflammatory Arthritis Center at the Hospital for Special Surgery in Manhattan and a researcher at Weill Cornell Medical College. Her focus is the …
Read more on New York Times